252 related articles for article (PubMed ID: 22153754)
1. The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma.
Sejima T; Iwamoto H; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
Urol Oncol; 2013 Oct; 31(7):1343-9. PubMed ID: 22153754
[TBL] [Abstract][Full Text] [Related]
2. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy.
Sejima T; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
Urol Int; 2012; 88(3):263-70. PubMed ID: 22398398
[TBL] [Abstract][Full Text] [Related]
3. Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.
Sun J; Ning H; Sun J; Qu X
Urol Oncol; 2016 May; 34(5):239.e9-15. PubMed ID: 26803433
[TBL] [Abstract][Full Text] [Related]
4. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.
Park YH; Baik KD; Lee YJ; Ku JH; Kim HH; Kwak C
BJU Int; 2012 Dec; 110(11 Pt B):E553-8. PubMed ID: 22578274
[TBL] [Abstract][Full Text] [Related]
5. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
6. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma.
Ohno Y; Nakashima J; Ohori M; Gondo T; Hatano T; Tachibana M
J Urol; 2012 Feb; 187(2):411-7. PubMed ID: 22177153
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
8. Fas expression in nephrectomized, non-cancerous specimens predicts post-nephrectomy chronic kidney disease progression in patients with renal and upper urinary tract malignancies.
Sejima T; Iwamoto H; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Amisaki T; Takenaka A
Urol Oncol; 2013 Nov; 31(8):1812-9. PubMed ID: 22591748
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
[TBL] [Abstract][Full Text] [Related]
10. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
Itano NB; Blute ML; Spotts B; Zincke H
J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Bozkurt O; Inanc M; Hacibekıroglu I; Esbah O; Seker M; Ulas A; Aydin K; Uysal M; Kücüköner M; Uncu D; Cıltas A; Unal OÜ; Durnali A; Demırcı U; Berk V; Tonyali O; Oksüzoglu B; Karaca H; Ozkan M
Anticancer Res; 2014 Aug; 34(8):4463-70. PubMed ID: 25075086
[TBL] [Abstract][Full Text] [Related]
12. Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status.
Ohno Y; Nakashima J; Ohori M; Tanaka A; Hashimoto T; Gondo T; Hatano T; Tachibana M
Int J Clin Oncol; 2014 Feb; 19(1):139-45. PubMed ID: 23299279
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma.
Ohno Y; Nakashima J; Ohori M; Hatano T; Tachibana M
J Urol; 2010 Sep; 184(3):873-8. PubMed ID: 20643463
[TBL] [Abstract][Full Text] [Related]
14. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.
Shvarts O; Seligson D; Lam J; Shi T; Horvath S; Figlin R; Belldegrun A; Pantuck AJ
J Urol; 2005 Mar; 173(3):725-8. PubMed ID: 15711252
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma.
Minárik I; Lašťovička J; Budinský V; Kayserová J; Spíšek R; Jarolím L; Fialová A; Babjuk M; Bartůňková J
Immunol Lett; 2013 May; 152(2):144-50. PubMed ID: 23721909
[TBL] [Abstract][Full Text] [Related]
16. Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma.
Brookman-Amissah S; Kendel F; Spivak I; Pflanz S; Roigas J; Klotz T; May M
BJU Int; 2009 May; 103(10):1375-80. PubMed ID: 19040527
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma.
Kim SP; Weight CJ; Leibovich BC; Thompson RH; Costello BA; Cheville JC; Lohse CM; Boorjian SA
Urology; 2011 Nov; 78(5):1101-6. PubMed ID: 21903243
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of small, organ-confined renal cell carcinoma (RCC) is not always favourable.
Shindo T; Masumori N; Kobayashi K; Fukuta F; Hirobe M; Tonooka A; Hasegawa T; Kitamura H; Tsukamoto T
BJU Int; 2013 May; 111(6):941-5. PubMed ID: 23350965
[TBL] [Abstract][Full Text] [Related]
19. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma.
de Martino M; Pantuck AJ; Hofbauer S; Waldert M; Shariat SF; Belldegrun AS; Klatte T
J Urol; 2013 Dec; 190(6):1999-2004. PubMed ID: 23831313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
